Rapid Diagnostic Methods for Tuberculosis: A Comparative Analysis of GeneXpert and Microscopy

Tuberculosis (TB) continues to be a significant global health issue, standing out as one of the leading infectious causes of death around the world. Quick and precise diagnosis is essential for controlling its spread and starting treatment on time. While traditional sputum smear microscopy is straightforward and cost-effective, it has its drawbacks—particularly when it comes to sensitivity in HIV-positive individuals and those with low bacterial counts, and it also fails to identify drug resistance. The advent of molecular diagnostic methods, like the GeneXpert MTB/RIF assay, has transformed TB diagnosis by enabling automated detection of Mycobacterium tuberculosis DNA and the simultaneous identification of rifampicin resistance in just two hours. This analytical review looks at how GeneXpert stacks up against microscopy by examining data from WHO reports and studies on PubMed. The results consistently indicate that GeneXpert offers greater sensitivity and specificity, especially in cases that are smear-negative and among children with TB, while also allowing for quick detection of drug resistance. However, its higher cost and the need for specific infrastructure can be hurdles in resource-limited settings. Microscopy still holds value for initial screenings and tracking treatment progress. In summary, combining GeneXpert with traditional microscopy in national TB control programs could significantly improve diagnostic accuracy, speed up case detection, and play a crucial role in meeting the targets set by WHO’s End TB Strategy.